Thanks for the link, Zeuss! I'm just now reading about today's PR, I was looking for some actual "bad news" to justify the sell-off.
Well, not only is there no bad news, this safety data looks FANTASTIC!
From your linked article,
"These results earn leronlimab exceptionally high marks with respect to safety, but should come as no surprise because over 750 HIV patients have taken the drug without any safety issues. In the coming days or weeks the company plans on following up with the efficacy part of the trial and reveals whether or not it met its primary endpoint of clinical improvement assessed on a 12 point scale. The reason for optimism that leronlimab will crush its primary endpoint lies in the huge statistical reduction in SAEs. Scott Kelly, M.D., CytoDyn’s Chief Medical Officer, commented,
“We believe the significant reduction in SAEs in the leronlimab group ultimately translates into improved patient clinical outcomes."
Success!!!!
SP to follow.
News 
Market Data 
Discover 
